THE RISK OF THROMBOEMBOLIC COMPLICATIONS WITHOUT ANTICOAGULATION AFTER SURGICAL AORTIC VALVE REPLACEMENT WITH A BIOPROSTHESIS

Background: Guidelines recommend that patients (pts) undergoing bioprosthetic aortic valve replacement (AVR) receive at least 3 months of anticoagulation with warfarin because it is believed to reduce thromboembolic events.

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2015-03, Vol.65 (10), p.A2041-A2041
Main Authors: Berger, Peter B, Vedamurthy, Deepak, Casale, Alfred, Sun, Haiyan, Benoit, Charles, Ferrari, Ashley, Trocciola, Susan, Sayed, Ibrahim Ismail, Carter, Russell
Format: Article
Language:English
Subjects:
Cardiology
Cardiovascular
Drug therapy
Internal Medicine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Guidelines recommend that patients (pts) undergoing bioprosthetic aortic valve replacement (AVR) receive at least 3 months of anticoagulation with warfarin because it is believed to reduce thromboembolic events.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(15)62041-1